The present invention relates to obeticholic acid:
The present invention relates to obeticholic acid:
The present invention relates to obeticholic acid:
or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
C07J 51/00 - Stéroïdes normaux à squelette du cyclopenta[a]hydrophénanthrène non modifié non prévus dans les groupes
2.
COMPOSITION FOR CORRECTION OF NUTRITIONAL DEFICIENCIES UNDERLYING MOOD DISORDER
Disclosed in- certain embodiments are compositions and methods for treating, reducing or ameliorating symptoms of a mood disorder and/or re-establishment of homeostasis of nutritional, deficiencies.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
4.
VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO)
The invention relates to 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide (velusetrag) or a pharmaceutically acceptable salt thereof for use in a method of treating idiopathic chronic intestinal pseudo-obstruction (CIPO), neuropathic chronic intestinal pseudo-obstruction, or chronic intestinal pseudo-obstruction being secondary to neurodegeneration or to demyelinating conditions in a patient suffering from said diseases or conditions.
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.
The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
8.
BIOMARKERS FOR DETERMINING TREATMENT OF ULCERATIVE COLITIS WITH FILGOTINIB
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present application provides a compound of formula I:
The present application provides a compound of formula I:
The present application provides a compound of formula I:
or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1-R10, m, n, p, and are as described herein. The present invention relates generally to F modulators and to methods of making and using said compounds.
C07J 43/00 - Stéroïdes normaux ayant un hétérocycle contenant de l'azote non condensé ou condensé en spiro avec le squelette du cyclopenta[a]hydrophénanthrène
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
C07J 31/00 - Stéroïdes normaux contenant un ou plusieurs atomes de soufre n'appartenant pas à un hétérocycle
C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle
C07J 71/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène condensé avec un hétérocycle
16.
PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
17.
PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
18.
FERMENTATION PRODUCT FOR THE TREATMENT OF INFLAMMATORY DISEASES
The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentary and/or pharmaceutically acceptable components or comprised in medical food or nutritional composition. The fermentation product and is useful for the treatment and/or prevention of inflammatory diseases, in particular, inflammatory bowel disease.
A61K 36/82 - Theaceae (famille du théier), p. ex. camélia
A61K 36/9066 - Curcuma, p. ex. curcuma, zédoaire ou curcuma amada
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The object of the present invention is to use the strain of bacteria named Lacticaseibacillus paracasei DG® CNCM I-1572 DSM 34154 for use in a method of treating dysbiosis, particularly in patients with IBS (Irritable Bowel Syndrome), preferably without constipation, who have high fecal levels of Collinsella aerofaciens.
The present invention discloses salts of a Compound 1:
The present invention discloses salts of a Compound 1:
The present invention discloses salts of a Compound 1:
useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
H04L 67/51 - Découverte ou gestion de ceux-ci, p. ex. protocole de localisation de service [SLP] ou services du Web
H04W 4/80 - Services utilisant la communication de courte portée, p. ex. la communication en champ proche, l'identification par radiofréquence ou la communication à faible consommation d’énergie
The present invention relates to FXR agonist compounds and methods of use thereof for treating, ameliorating, or promoting recovery from diseases and disorders, such as acute diseases of the liver, for example, severe alcohol-associated hepatitis.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
The present disclosure relates to a combination of an FXR agonist and a fibrate. Also disclosed is use of the combination for the treatment, amelioration or prevention of an FXR mediated disease or condition, such as primary biliary cholangitis (PBC).
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Anti-viral agents; Antifungal medication; Pharmaceutical preparations for treating rheumatological diseases; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Antiviral drugs for treating HIV; Pharmaceutical preparations for treating arthritis.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Anti-viral agents; Antifungal medication; Pharmaceutical preparations for treating rheumatological diseases; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Antiviral drugs for treating HIV; Pharmaceutical preparations for treating arthritis.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietary supplements; Pharmaceutical products and preparations including live milk enzymes and probiotic enzymes for medical and pharmaceutical use, namely, lactic ferment containing Lactobacillus paracasei CNCM I-1572; dietary supplement beverage for restoring gut microbiota balance, reducing diarrhea incidence and duration and improving symptoms in irritable bowel syndrome (IBS) for medical use; dietary supplemental drinks in the nature of vitamin beverages; dietary fiber to rebalance intestinal bacterial flora, strengthening the immune system, and assisting digestion; biological nutritional supplements for medical use; probiotic bacteria preparations for medical use
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietary supplements; Dietary fiber to rebalance intestinal bacterial flora, strengthening the immune system, and assisting digestion; Nutritional supplements; Pharmaceutical preparations, in particular, milk enzymes and probiotic enzymes for use in improving symptoms in irritable bowel syndrome (IBS); Dietary supplemental drinks in the nature of vitamin and mineral beverages, dietary supplemental drinks for medical use
The present invention relates to a pharmaceutical composition in the form of orodispersible tablets comprising betamethasone phosphate together with pharmaceutically acceptable excipients. A process for obtaining the composition comprising betamethasone phosphate and its use in the treatment and/or prevention of diseases in which betamethasone phosphate is useful is also described.
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The present invention relates to a compound of formula (I) for use in the treatment of disorders and/or conditions associated with high trimethylamine (TMA) and/or trimethylamine N-oxide (TMAO) plasma levels, or for use in the treatment of disorders and/or conditions associated with a high ratio of TMA/TMAO plasma concentrations as well as relative composition and method of preparation.
A61K 31/205 - Sels d'addition d'acides organiques avec des aminesSels d'ammonium quaternaire internes, p. ex. bétaïne, carnitine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07C 229/22 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé le squelette carboné étant substitué de plus par des atomes d'oxygène
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
C07J 31/00 - Stéroïdes normaux contenant un ou plusieurs atomes de soufre n'appartenant pas à un hétérocycle
C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle
C07J 71/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène condensé avec un hétérocycle
36.
USE OF LACTOBACILLUS PARACASEI BACTERIAL STRAINS IN THE TREATMENT OF NEWBORNS
The present invention relates to at least one strain of bacteria belonging to the species Lactobacillus paracasei, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-01 DSM 26760, and compositions thereof for use in newborns and/or from 1 month to ≤12 months subjects in the treatment, preventive and/or curative, of gastro-intestinal tract disorders of an inflammatory and/or functional nature, gastro-intestinal infections by pathogenic micro-organisms, gastro-intestinal infections by parasites, allergies, immune-mediated or autoimmune disorders, and in the support of the subject's growth.
Lactobacillus paracaseiAllium sativumCassia angustifoliaCassia angustifolia, and compositions containing it, for use in treatment and/or prevention of trimethylaminuria (TMAU).
A61K 36/8962 - Allium, p. ex. oignon, poireau, ail ou ciboulette
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
38.
Compound useful for the treatment of degenerative and inflammatory diseases
A novel compound able to inhibit JAK is disclosed, that comprises a compound of Formula 1:
The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
40.
FERMENTATION PRODUCT FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH METABOLIC SYNDROME AND HEPATIC STEATOSIS
The present inven on relates to a bacterial strain, Lac plan bacillus plantarum DSM 33683, and to a composi on comprising the fermenta on product of this bacterial strain, obtained in the presence of at least one plant extract. The composi on is useful in the treatment and/or preven on of diseases associated with metabolic syndrome or in the treatment and/or preven on of insulin resistance syndrome and in the treatment and/or preven on of hepa c steatosis. It also relates to the process for obtaining the fermenta on product and the composi on comprising the same.
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 5/00 - Médicaments pour le traitement des troubles du système endocrinien
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceutical preparations for the protection of the esophagus in case of gastroesophageal reflux; Medicines for the treatment of gastrointestinal diseases; Gastrointestinal treatment preparations; Gastroenteric treatment preparations; Pharmaceutical preparations for the treatment of esophagitis; Pharmaceutical cough treatment preparations; Pharmaceutical preparations for treating asthma Medical devices for use in treating gastroesophageal reflux
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pomades for cosmetic purposes; Salves [non-medicated]. Pharmaceuticals; Pomades for medical purposes; Medicinal ointments; Medicated ointments for application to the skin; Food supplements; Dietary and nutritional supplements; Pharmaceutical drugs; Cardiovascular drugs for use in treating hypertension; Cardiovascular drugs used in treating arrhythmias; Cardiovascular drugs used in angina pectoris; Cardiovascular drugs used in myocardial infarction; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Cardiovascular drugs used in treating congestive heart failure (CHF); Cardiovascular drugs used in treating shocks; Cardiovascular agents for medical purposes; Cardiovascular preparations; Pharmaceutical preparations for the treatment of cardiovascular disease; Cardiovascular pharmaceuticals; Medicated mouth care preparations; Blood tonics. Apparatus for drug administration; Drug-coated stents for thrombosis; Cardiovascular instruments; Apparatus for the diagnosis of cardiovascular diseases; Cardiovascular catheters; Heart monitors; Apparatus for blood monitoring [for medical use]; Pharmaceutical instruments.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pomades for cosmetic purposes; Salves [non-medicated]. Pharmaceuticals; Pomades for medical purposes; Medicinal ointments; Medicated ointments for application to the skin; Food supplements; Dietary and nutritional supplements; Pharmaceutical drugs; Cardiovascular drugs for use in treating hypertension; Cardiovascular drugs used in treating arrhythmias; Cardiovascular drugs used in angina pectoris; Cardiovascular drugs used in myocardial infarction; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Cardiovascular drugs used in treating congestive heart failure (CHF); Cardiovascular drugs used in treating shocks; Cardiovascular agents for medical purposes; Cardiovascular preparations; Pharmaceutical preparations for the treatment of cardiovascular disease; Cardiovascular pharmaceuticals; Medicated mouth care preparations; Blood tonics. Apparatus for drug administration; Drug-coated stents for thrombosis; Cardiovascular instruments; Apparatus for the diagnosis of cardiovascular diseases; Cardiovascular catheters; Heart monitors; Apparatus for blood monitoring [for medical use]; Pharmaceutical instruments.
The invention relates to 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8- azabicyclo[3.2.1]oct-3-yl}amide (velusetrag) or a pharmaceutically acceptable salt thereof for use in a method of treating idiopathic chronic intestinal pseudo-obstruction (CIPO), neuropathic chronic intestinal pseudo-obstruction, or chronic intestinal pseudo-obstruction being secondary to neurodegeneration or to demyelinating conditions in a patient suffering from said diseases or conditions.
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
47.
USE OF A COMPOSITION COMPRISING MICROORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTYRIC ACID, FOLIC ACID OR NIACIN AND/OR DECREASE THE INTESTINAL PRODUCTION OF SUCCINIC ACID
Use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid.
Use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid.
Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.
The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentary and/or pharmaceutically acceptable components or comprised in medical food or nutritional composition. The fermentation product and is useful for the treatment and/or prevention of inflammatory diseases, in particular, inflammatory bowel disease.
A61K 36/906 - Zingiberaceae (famille du gingembre)
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention discloses salts of a Compound 1:
useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
H04L 67/51 - Découverte ou gestion de ceux-ci, p. ex. protocole de localisation de service [SLP] ou services du Web
H04W 4/80 - Services utilisant la communication de courte portée, p. ex. la communication en champ proche, l'identification par radiofréquence ou la communication à faible consommation d’énergie
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Education services relating to pharmacy; Publication of the results of clinical trials for pharmaceutical preparations; Adult education services relating to pharmacy; Providing of training in the field of health care and nutrition; Provision of educational services relating to health; Education services relating to health; Provision of educational courses in the field of diet and health care; Training in the field of medicine; Organization of seminars and conventions in the field of medicine. Consultancy pertaining to pharmacology; Consultancy relating to pharmaceutical research and development; Consultancy in the field of pharmaceutical research; Development of pharmaceutical preparations and medicines; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the pharmaceutical and biotechnology fields; Research on the subject of pharmaceuticals. Pharmaceutical advice; Pharmaceutical services; Medication counseling; Advisory services relating to pharmaceuticals; Provision of pharmaceutical information; Pharmacy advice; Medical services; Professional consultancy relating to health; Public health counseling; Health advice and information services; Individual medical counseling services provided to patients; Human healthcare services; Information services relating to health care; Consulting services relating to health care.
51.
LACTICASEIBACILLUS PARACASEI DG® CNCM I‐1572 DSM 34154 FOR USE IN A METHOD OF TREATING DYSBIOSIS IN PATIENTS WITH IBS
The object of the present invention is to use the strain of bacteria named Lacticaseibacillus paracasei DG® CNCM I1572 DSM 34154 for use in a method of treating dysbiosis, particularly in patients with IBS (Irritable Bowel Syndrome), preferably without constipation, who have high fecal levels of Collinsella aerofaciens.
The present invention relates to bacterial strains for use in the treatment of vitamin D deficiency and/or insufficiency and/or diseases, symptoms and/or disorders associated thereto. Furthermore, the present invention relates to compositions comprising at least one of said bacterial strains and at least one vitamin D, preferably vitamin D3, and to the use thereof in the treatment of said vitamin D deficiency and/or insufficiency and/or diseases, symptoms or disorders associated thereto.
The present invention describes a pharmaceutical and/or nutritional composition comprising methylfolate in the form of granules, together with a carnitine derivative salt, pharmaceutically acceptable excipients, and optionally other pharmaceutical or nutraceutical active ingredients. The composition is useful for oral administration. The invention also relates to the process for obtaining the composition comprising methylfolate in the form of granules and the use thereof for the treatment of disorders associated with a reduction of methylfolate, wherein methylfolate is useful.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Laxatives; laxatives for detoxification purposes; medicines
for intestinal disorders; pharmaceutical preparations for
treating gastrointestinal disorders.
56.
FERMENTED SUPERNATANT AND POSTBIOTIC COMPOSITIONS USEFUL IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES.
The present invention relates to a supernatant obtained by the fermentation of a bacterial strain selected from the group of: Akkermansia muciniphila, Lactobacillus rhamnosus, Bifidobacterium breve Reuter and Lactobacillus paracasei in the presence of at least one plant extract selected from the group of: Allium sativum, Salvia miltiorrhiza, Zingiber officinale, Myrciaria dubia, Garcinia cambogia, Garcinia mangosteen, Cassia angustifolia leaves and Nelumbo nucifera leaves. It is also described the process for obtaining such supernatant, the composition comprising thereof and its use in the treatment and/or prevention of diseases associated with cardiovascular diseases.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Laxatives; Laxatives for detoxification purposes; Medicines for intestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders.
The present invention relates to a process to prepare solid pharmaceutical forms comprising a quantity of mesalazine comprised between 75 and 95%, i.e. between 1000 and 1600 mg of drug per dosage unit. Furthermore, the present invention relates to a granulate and/or tablets obtained/obtainable with the process according to the invention, preferably coated to allow the con-trolled release of the drug. Finally, the present invention relates to the use of the granulate and/or the tablets as a medicament, preferably for the treatment of chronic inflammatory pathologies that preferably affect the intestinal tract.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Laxatives; laxatives for detoxification purposes; medicines for intestinal disorders; pharmaceutical preparations for treating gastrointestinal disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Laxatives; Laxatives for detoxification purposes; Medicines for intestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Laxatives; Laxatives for detoxification purposes; Medicines for intestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders.
62.
USE OF LACTOBACILLUS PARACASEI BACTERIAL STRAINS IN THE TREATMENT OF NEWBORNS
The present invention relates to at least one strain of bacteria belonging to the species Lactobacillus paracasei, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-01 DSM 26760, and compositions thereof for use in newborns and/or from 1 month to ?12 months subjects in the treatment, preventive and/or curative, of gastro-intestinal tract disorders of an inflammatory and/or functional nature, gastro-intestinal infections by pathogenic micro-organisms, gastro-intestinal infections by parasites, allergies, immune-mediated or autoimmune disorders, and in the support of the subject's growth.
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
63.
COMPOSITIONS COMPRISING BACTERIAL STRAINS FOR USE IN INCREASNG THE BIOAVAILABILITY OF AMINO ACIDS DERIVED FROM PROTEINS
Compositions are described and related methods and food products for increasing the blood bioavailability of amino acids derived from proteins, preferably proteins of plant origin, based on a mixture M including at least one bacterial strain, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-S01™ DSM 26760. Furthermore, the mixture M is described, as well as the compositions and related methods and food products based on mixture M and further comprises at least one protein, preferably proteins of plant origin, or a peptide or an amino acid.
A composition comprising a mixture comprising or, alternatively, consisting of: at least one bacterial strain selected from a group comprising or, alternatively, consisting of bacterial strains belonging to the species Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium bifidum and Bifidobacterium animalis subsp. Lactis, and preferably, at least one extract of at least one species of berries comprising a polyphenol fraction of said berries and a related method wherein said composition is used as an immunomodulatory and anti-inflammatory agent are disclosed.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p. ex. myrtille, canneberge ou airelle
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A composition comprising a mixture comprising or, alternatively, consisting of: at least one bacterial strain selected from a group comprising or, alternatively, consisting of bacterial strains belonging to the species Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium bifidum and Bifidobacterium animalis subsp. Lactis, and preferably, at least one extract of at least one species of berries comprising a polyphenol fraction of said berries. and a related method wherein the composition is an immunomodulatory and anti-inflammatory agent are described.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 36/45 - Ericaceae ou Vacciniaceae (famille de la bruyère ou de la myrtille), p. ex. myrtille, canneberge ou airelle
67.
Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, for example irritable bowel syndrome (IBS) are described.
Bacterial strains including B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BIIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) are described. Furthermore, compositions are further described comprising a mixture of at least one or more of the aforementioned bacterial strains and, optionally, at least one further bacterial strain, selected from a bacterial strain L. casei DG® (CNCM I-1572) and bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, irritable bowel syndrome (IBS).
The present invention relates to a bacterial strain of Bifidobacterium bifidum MIMBb23 sg (=BbfIBSCM) DSM 32708, compositions comprising said bacterial strain and the use thereof in methods for the treatment of gastrointestinal disorders, in particular functional gastrointestinal disorders, such as, for example, irritable bowel syndrome (IBS) or inflammatory bowel diseases (IBDs).
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
71.
PHARMACEUTICAL COMPOSITIONS IN THE FORM OF GEL CONTAINING XYLOGLUCAN AND ALCOHOLS FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS
The invention relates to gel compositions comprising pharmaceutical active ingredients. The composition comprises xyloglucan at a concentration between 0.1% and 10.0% by total weight of the composition, together with a primary alcohol at a concentration between 20.0 and 50.0% by total weight of the composition. The invention also describes a process for the preparation of the composition and its use in the treatment of pathologies wherein a controlled release of the active principle is useful.
The present invention relates to mucoadhesive gels comprising probiotics, to the process for their preparation and to their use for the prevention and treatment of pathologies of the 5 oral cavity.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and a fibrate. Also disclosed is use of the combination for the treatment, amelioration or prevention of an FXR mediated disease or condition, such as primary biliary cholangitis (PBC).
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
74.
METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES
The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I
The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I
The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I
or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug thereof.
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
C07J 31/00 - Stéroïdes normaux contenant un ou plusieurs atomes de soufre n'appartenant pas à un hétérocycle
75.
NOVEL DNA SEQUENCES ENCODING HUMAN SCFVs ANTIBODIES WITH NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2 AND USES THEREOF
The present invention relates to a human single chain variable antigen-binding antibody fragment (scFv) that specifically binds to the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 virus and variants of the virus having one or more mutations in the spike protein, and has a neutralizing activity against SARS-CoV-2 and its spike protein variants, wherein said antibody fragment comprises at least one of the sequences selected from an amino acid sequence having any of SEQ ID NOs:2, 4, 6, 8, 10 or 12 or a sequence being at least 85% identical, preferably at least 90% identical, more preferably at least 95% identical, still more preferably at least 98% identical to any of said sequences, wherein the VH CDR3 sequence is ARDLSVAGAFDI (SEQ ID NO:44), wherein the VH and the VL variable regions are connected by a linker, and wherein the antibody fragment binds at least to the following residues within the human ACE2 receptor binding motif of the RBD of the spike protein of the SARS-CoV-2 virus L455, F456,Y473, N487 and Y489 and to a DNA sequence encoding said fragments, pharmaceutical compositions comprising said antibody fragments and derivatives thereof as well as said antibody fragments and the pharmaceutical compositions comprising them for use in a method of preventing or treating a SARS-CoV-2-virus-mediated disorder, preferably COVID-19.
A novel compound able to inhibit JAK is disclosed, that comprises a compound of Formula I:
The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention describes a pharmaceutical and/or nutritional composition comprising methylfolate in the form of granules, together with a carnitine derivative salt, pharmaceutically acceptable excipients, and optionally other pharmaceutical or nutraceutical active ingredients. The composition is useful for oral administration. The invention also relates to the process for obtaining the composition comprising methylfolate in the form of granules and the use thereof for the treatment of disorders associated with a reduction of methylfolate, wherein methylfolate is useful.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
Produits et services
Raw materials [chemical], chemicals, additives and chemical
compounds intended for industry for formulation and
preparation of pharmaceutical, parapharmaceutical,
nutraceutical, nutritional, food and dietary substances,
food and dietary substances for medical use, dietary food
and substances for babies for medical use, functional and
nutraceutical food for medical use, food supplements for
medical use, food supplements for humans, pharmaceutical
products and food supplements, in accordance with EU
regulation 2017/745; bacteriological preparations other than
those for medical and veterinary use; bacteriological
cultures to be added to foods, milk and dairy products,
including fermented milk products, other than for medical
and veterinary use; cultures of microorganisms not for
medical purposes; cultures of microorganisms for use in the
manufacture of food and beverages; preparations based on
microorganisms, not for medical or veterinary use; bacterial
substances for industrial use; bacteria used in food
production; chemical preparations for use in the manufacture
of cosmetics; bacterial preparations for the food industry;
additive bacterial cultures for food products; bacterial
preparations and cultures not for medical use; lactic
ferments and bacterial preparations used for production of
foods; antioxidants, fatty acids, proteins, enzymes,
liposomes, cultures of microorganisms, bacteria to produce
lactic acid and probiotic compounds all intended for the
production of pharmaceuticals, dietary compounds for human
use, baby food, food supplements, nutritional supplements,
dietary supplements, food supplements for medical use and
dietary foods; probiotic bacteria for the food industry;
preparations of probiotic bacteria [not for medical use];
fermentation extracts for industrial use. Cosmetic products containing live or dead microorganisms;
cosmetics and cosmetic preparations based on microorganisms,
lactic bacteria and / or bifidobacterial; functional
cosmetics based on microorganisms, lactic bacteria and / or
bifidobacterial; non-medicated cosmetics; cosmetics
containing hyaluronic acid and microorganisms. Preparations of microorganisms for medical or veterinary
use; bacteriological preparations for medical and veterinary
use; pharmaceutical products and preparations, including
pharmaceutical products, parapharmaceuticals, lactic
ferments, probiotic ferments, probiotics, nutraceuticals,
nutritional; pharmaceutical products and food supplements,
in accordance with EU regulation 2017/745; bacteriological
cultures to add to milk, dairy products and fermented milk
for medical purposes; lactic bacteria for medical purposes;
food additives based on milk and dairy products, including
fermented milk products, for use as a dietary supplement
(not for medical purposes); vitamins; dietary fibers to aid
digestion; dietary fibers for use as an ingredient in the
manufacture of dietary supplements, vitamin drinks, dietary
drinks for medical use; food and dietetic substances for
medical use, food and dietetic substances for infants for
medical use, functional foods and nutraceuticals for medical
use, food supplements for medical use and food supplements
for humans comprising at least one selected compound trace
elements, mineral salts, oxides of metals, metal hydroxides,
phosphoric acid salts, vitamins, proteins, milk proteins,
microelements, organic acids and their salts, inorganic
acids and their salts, saturated or unsaturated fatty acids,
oils, fats and lipids of vegetable origin and / or animal,
amino acids, glucose, starch, rice starch, carbohydrates,
saccharic esters of fatty acids, sunflower lecithin and
lecithin, omega-3 and omega-6; probiotic bacterial
preparations for medical and animal use. Wholesale and retail services for the benefit of third
parties including by mail order and through the means of
communication including the internet, in relation to raw
materials [chemical], chemicals, additives and chemical
compounds intended for industry for formulation and
preparation of pharmaceutical, parapharmaceutical,
nutraceutical, nutritional, food and dietary substances,
food and dietary substances for medical use, dietary food
and substances for babies for medical use, functional and
nutraceutical food for medical use, food supplements for
medical use, food supplements for humans, medical
preparations, namely medical devices pursuant to EU
regulation 2017/745, pharmaceutical products and food
supplements, in accordance with EU regulation 2017/745,
bacteriological preparations other than those for medical
and veterinary use, bacteriological cultures to be added to
foods, milk and dairy products, including fermented milk
products, other than for medical and veterinary use,
cultures of microorganisms not for medical purposes,
cultures of microorganisms for use in the manufacture of
food and beverages, preparations based on microorganisms,
not for medical or veterinary use, bacterial substances for
industrial use, bacteria used in food production, chemical
preparations for cosmetics, bacterial preparations for the
food industry, additive bacterial cultures for food
products, bacterial preparations and cultures not for
medical use, lactic ferments and bacterial preparations used
for production of foods, antioxidants, fatty acids,
proteins, enzymes, liposomes, cultures of microorganisms,
bacteria to produce lactic acid and probiotic compounds all
intended for the production of pharmaceuticals, dietary
compounds for human use, baby food, food supplements,
nutritional supplements, dietary supplements, food
supplements for medical use and dietary foods, probiotic
bacteria for the food industry, preparations of probiotic
bacteria [not for medical use], fermentation extracts for
industrial use, probiotic bacterial preparations for medical
and animal use; wholesale and retail services for the
benefit of third parties including by mail order and through
the means of communication including the internet, in
relation to cosmetic products containing live or dead
microorganisms, cosmetics and cosmetic preparations based on
microorganisms, lactic bacteria and / or bifidobacterial,
functional cosmetics based on microorganisms, lactic
bacteria and / or bifidobacterial, non-medicated cosmetics,
cosmetics containing hyaluronic acid and microorganisms;
wholesale and retail services for the benefit of third
parties including by mail order and through the means of
communication including the internet, in relation to
preparations of microorganisms for medical or veterinary
use, bacteriological preparations for medical and veterinary
use, pharmaceutical products and preparations, including
pharmaceutical products, parapharmaceuticals, lactic
ferments, probiotic ferments, probiotics, nutraceuticals,
nutritional, medical preparations, namely medical devices
pursuant to EU regulation 2017/745, pharmaceutical products
and food supplements, in accordance with EU regulation
2017/745, bacteriological cultures to add to milk, dairy
products and fermented milk for medical purposes, lactic
bacteria for medical purposes, food additives based on milk
and dairy products, including fermented milk products, for
use as a dietary supplement (not for medical purposes),
vitamins, dietary fibers to aid digestion, dietary fibers
for use as an ingredient in the manufacture of dietary
supplements, vitamin drinks, dietary drinks for medical use,
food and dietetic substances for medical use, food and
dietetic substances for infants for medical use, functional
foods and nutraceuticals for medical use, food supplements
for medical use and food supplements for humans comprising
at least one selected compound trace elements, mineral
salts, oxides of metals, metal hydroxides, phosphoric acid
salts, vitamins, proteins, milk proteins, microelements,
organic acids and their salts, inorganic acids and their
salts, saturated or unsaturated fatty acids, oils, fats and
lipids of vegetable origin and / or animal, amino acids,
glucose, starch, rice starch, carbohydrates, saccharic
esters of fatty acids, sunflower lecithin and lecithin,
omega-3 and omega-6.
36 - Services financiers, assurances et affaires immobilières
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Promoting public awareness of treatment guidelines;
promoting public awareness of inflammatory and autoimmune
diseases; administratively assisting patients in enrolling
in pharmaceutical reimbursement and benefit programs. Financially assisting patients, pharmacists, and healthcare
providers with respect to reimbursement of medicines. Information and advisory services relating to
pharmaceuticals, diseases and medical conditions and
treatment, including such services provided on-line from a
computer network or the Internet; providing information and
advisory services regarding the diagnosis and treatment of
diseases and medical disorders.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
Produits et services
Raw materials [chemical], chemicals, chemical additives and compositions for use in industry for the formulation and preparation of the following goods: Pharmaceuticals, Parapharmaceutical preparations, nutraceutical preparations, Nutritional products, Dietetic food and substances, dietetic food and substances adapted for medical use, Dietetic food and substances for babies, adapted for medical use, Functional foodstuffs and nutraceuticals for medical purposes, Food-supplements for medical use, Dietary supplements for human beings; Bacteriological preparations, other than for medical and veterinary use; Bacteriological cultures for adding to food, milk and dairy products, including fermented milk products, other than for medical and veterinary use; Cultures of microorganisms other than for medical use; Cultures of microorganisms for use in making food and beverages; Preparations of microorganisms, other than for medical and veterinary use; Bacterial substances for industrial use; Bacteria for use in food manufacture; Chemical preparations for use in the manufacture of cosmetics; Bacterial preparations for the food industry; Bacterial cultures for addition to food products; Bacterial preparations and cultures other than for medical use; Milk ferments and bacterial preparations for use in producing foodstuffs; Antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria for producing lactic acid and probiotic compositions, all for use in producing the following goods: Pharmaceuticals, Dietetic compounds for humans, Food for babies, Food supplements, Nutritional supplements, Dietetic supplements, Food-supplements for medical use and Dietetic food; Probiotic bacteria for the food industry; Preparations of probiotic bacteria, other than for medical; Fermentation extracts for industrial purposes. Pharmaceuticals; Medical and veterinary preparations containing live and/or dead microorganisms; Sanitary preparations for medical purposes; Preparations of microorganisms for medical or veterinary use; Bacteriological preparations for medical and veterinary purposes; Pharmaceuticals and pharmaceutical preparations, including the following goods: Pharmaceuticals, Parapharmaceutical preparations, Milk ferments, Probiotic ferments, Probiotics, Nutraceuticals, Nutritional preparations; Medical preparations for food, nutritional, dietetic, vitamin, nutraceutical, probiotic, prebiotic and pharmaceutical use; Pharmaceutical preparations and dietary supplements; Bacteriological cultures for adding to milk, dairy products and fermented milk, for medical use; Lactic bacteria, For medical purposes; Food additives based on milk and dairy products, including fermented milk products, for use as dietary supplement (not for medical use); Vitamins; Dietary fiber to aid digestion; Dietary fibre for use as ingredients in the production of dietary supplements, vitamin drinks, dietetic beverages adapted for medical use; Dietetic food and substances adapted for medical use, dietetic food and substances for babies for medical use, functional and nutraceutical food, not for medical use, dietary supplements for medical use and dietary supplements for human beings featuring at least one of the following compounds: Trace elements, Mineral salts, Metal oxides, Metal hydroxides, Salts of phosphoric acid, Vitamins, Protein, Antioxidants, Enzymes, Liposomes, Hyaluronic acid, Milk proteins, Microelements, Organic acids and their salts, Inorganic acids and their salts, Saturated and unsaturated fatty acids, Oils, fats and lipids of plant and/or animal origin, Amino acid, Glucose, Stiffeners, Rice starch, Carbohydrates, Saccharic esters in fatty acids, Lecithin and sunflower lecithin, Omega 3 and Omega-6; Probiotic bacterial formulations for medical use, Probiotic bacterial preparations for animals. Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: Raw materials [chemical], chemicals, chemical additives and compounds for use in industry for the formulation and preparation in relation the following goods: pharmaceuticals, Parapharmaceuticals, Nutraceuticals, nutritional, dietetic food and substances, Dietetic foodstuffs and substances adapted for medical use, Dietetic food and substances for babies adapted for medical use, Functional foodstuffs and nutraceuticals for medical purposes, Nutritional additives for medical purposes, Dietary supplements for human beings, Bacteriological preparations, other than for medical and veterinary use, Bacteriological cultures for adding to food, milk and dairy products, including fermented milk products, Not for medical or veterinary purposes, Cultures of microorganisms other than for medical use, cultures of microorganisms for use in making food and beverages, preparations based on microorganisms, Not for medical or veterinary purposes, bacterial substances for industrial use, Bacteria for use in food manufacture, Chemical preparations for use in cosmetic products, Bacterial preparations for the food industry, Bacterial cultures for addition to food products, Bacterial preparations and cultures not for medical use, Milk ferments and bacterial preparations for use in producing foodstuffs, Antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria for producing lactic acid and probiotic compositions, all for use in producing the following goods: pharmaceuticals, Dietetic compounds for humans, Baby food, Nutritional supplements, Nutritional supplements, dietary supplements, Dietary supplements for medical purposes and dietetic food, probiotic bacteria for the food industry, Probiotic bacterial preparations (not for medical use), fermentation extracts for industrial purposes; Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: pharmaceuticals, Medical and veterinary preparations containing live and/or dead microorganisms, Sanitary preparations for medical purposes, Preparations of microorganisms for medical and veterinary purposes, Bacteriological preparations for medical and veterinary use, Pharmaceuticals and pharmaceutical preparations, including the following goods: pharmaceuticals, Parapharmaceuticals, Milk ferments, Probiotic ferments, Probiotics, Nutraceuticals, nutritional, Medical preparations for food, nutritional, dietetic, vitamin, nutraceutical, probiotic, prebiotic and pharmaceutical use, pharmaceuticals and food supplements, Bacteriological cultures for adding to milk, dairy products and fermented milk products, for medical use, food additives based on milk and dairy products, including fermented milk products, for use as dietary supplement (not for medical use), vitamins, Dietary fiber to aid digestion, Dietary fibre for use as an ingredient in the production of dietary supplements, Vitamin-fortified beverages, Dietetic beverages adapted for medical, Dietetic food and substances adapted for medical use, dietetic food and substances for babies for medical use, functional and nutraceutical food, not for medical use, dietary supplements for medical use and dietary supplements for human beings featuring at least one of the following compounds: trace elements, mineral salts, Metal oxides, Metal hydroxides, Phosphoric acid salts, vitamins, Proteins, antioxidants, enzymes, liposomes, hyaluronic acid, milk protein, Microelements, Organic acid salts, Inorganic acids and salts thereof, saturated or unsaturated fatty acids, oils, fats and lipids of plant and/or animal origin, amino acids, Glucose, Starch, rice starch, Carbohydrates, Saccharic esters in fatty acids, Lecithin and Sunflower lecithin, omega 3 and omega-6, Probiotic bacterial preparations for medical purposes and for animals.
The present invention relates to compound according to Formula I:
or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.
The present application provides a compound of formula I:
are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.
C07J 31/00 - Stéroïdes normaux contenant un ou plusieurs atomes de soufre n'appartenant pas à un hétérocycle
C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle
C07J 43/00 - Stéroïdes normaux ayant un hétérocycle contenant de l'azote non condensé ou condensé en spiro avec le squelette du cyclopenta[a]hydrophénanthrène
C07J 71/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène condensé avec un hétérocycle
84.
Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
The present invention discloses salts of a Compound 1:
useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
H04W 4/80 - Services utilisant la communication de courte portée, p. ex. la communication en champ proche, l'identification par radiofréquence ou la communication à faible consommation d’énergie
H04L 67/51 - Découverte ou gestion de ceux-ci, p. ex. protocole de localisation de service [SLP] ou services du Web
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
H04W 92/18 - Interfaces entre des dispositifs hiérarchiquement similaires entre des dispositifs terminaux
85.
Probiotics for use in the treatment of diverticulosis and diverticular disease
The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; dietetic food
and substances adapted for medical or veterinary use, food
for babies; dietary supplements for human beings and
animals; plasters, materials for dressings; dietetic food
and substances for babies; dietetic food and substances for
babies adapted for medical use; food supplements: dietary
supplements; nutraceuticals for use as dietary supplements;
functional foodstuffs and nutraceuticals for medical
purposes; nutritional additives for medical use; foods for
special medical purposes; medical preparations, in
particular medical devices pursuant to regulation
EU2017/745; drug delivery agents; delivery agents for
dietary supplements; active ingredients and pharmaceutical
and veterinary active substances; pharmaceutical
preparations for inhalers; medicinal sprays; inhalants. Surgical, medical, and veterinary apparatus and instruments;
therapeutic and assistive devices adapted for persons with
disabilities; apparatus, devices and articles for nursing
infants; inhalers for medical use; spray bottles
[vaporizers] for medical use; cans [spray] for medical use;
aerosol dispenser for medical purposes; pipetting
instruments for medical use; apparatus for administering
drugs by inhalation.
87.
Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
Lactobacillus paracasei LPC-S01™ DSM 26760, and possibly. The compositions food products, methods and systems o the disclosure, can further comprise at least one protein, preferably proteins of plant origin, or a peptide or an amino acid, and in particular includes a food product comprising proteins, preferably of plant origin, and said mixture M of at least one bacterial strain.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
Produits et services
Raw materials [chemical], chemicals, chemical additives and compositions for use in industry for the formulation and preparation of the following goods: Pharmaceuticals, Parapharmaceutical preparations, nutraceutical preparations, Nutritional products, Dietetic food and substances, dietetic food and substances adapted for medical use, Dietetic food and substances for babies, adapted for medical use, Functional foodstuffs and nutraceuticals for medical purposes, Food-supplements for medical use, Dietary supplements for human beings; Bacteriological preparations, other than for medical and veterinary use; Bacteriological cultures for adding to food, milk and dairy products, including fermented milk products, other than for medical and veterinary use; Cultures of microorganisms other than for medical use; Cultures of microorganisms for use in making food and beverages; Preparations of microorganisms, other than for medical and veterinary use; Bacterial substances for industrial use; Bacteria for use in food manufacture; Chemical preparations for use in the manufacture of cosmetics; Bacterial preparations for the food industry; Bacterial cultures for addition to food products; Bacterial preparations and cultures other than for medical use; Milk ferments and bacterial preparations for use in producing foodstuffs; Antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria for producing lactic acid and probiotic compositions, all for use in producing the following goods: Pharmaceuticals, Dietetic compounds for humans, Food for babies, Food supplements, Nutritional supplements, Dietetic supplements, Food-supplements for medical use and Dietetic food; Probiotic bacteria for the food industry; Preparations of probiotic bacteria, other than for medical; Fermentation extracts for industrial purposes; Probiotic bacterial preparations for medical purposes and for animals. Cosmetics featuring live or dead microorganisms; Cosmetics and cosmetic preparations based on microorganisms, lactic bacteria and/or bifidobacteria; Functional cosmetics based on microorganisms, lactic bacteria and/or bifidobacteria; Non-medicated cosmetics; Cosmetics containing hyaluronic acid, Cosmetics featuring microorganisms. Preparations of microorganisms for medical or veterinary use; Bacteriological preparations for medical and veterinary purposes; Pharmaceuticals and pharmaceutical preparations, including the following goods: Pharmaceuticals, Parapharmaceutical preparations, Milk ferments, Probiotic ferments, Probiotics, Nutraceuticals, Nutritional preparations; Medical preparations for food, nutritional, dietetic, vitamin, nutraceutical, probiotic, prebiotic and pharmaceutical use; Pharmaceutical preparations and dietary supplements; Bacteriological cultures for adding to milk, dairy products and fermented milk, for medical use; Lactic bacteria, For medical purposes; Food additives based on milk and dairy products, including fermented milk products, for use as dietary supplement (not for medical use); Vitamins; Dietary fiber to aid digestion; Dietary fibre for use as ingredients in the production of dietary supplements, vitamin drinks, dietetic beverages adapted for medical use; Dietetic food and substances adapted for medical use, dietetic food and substances for babies for medical use, functional and nutraceutical food, not for medical use, dietary supplements for medical use and dietary supplements for human beings featuring at least one of the following compounds: Trace elements, Mineral salts, Metal oxides, Metal hydroxides, Salts of phosphoric acid, Vitamins, Protein, Milk proteins, Microelements, Organic acids and their salts, Inorganic acids and their salts, Saturated and unsaturated fatty acids, Oils, fats and lipids of plant and/or animal origin, Amino acid, Glucose, Stiffeners, Rice starch, Carbohydrates, Saccharic esters in fatty acids, Lecithin and sunflower lecithin, Omega 3 and Omega-6. Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: Raw materials [chemical], chemicals, chemical additives and compositions for use in industry for the formulation and preparation of the following goods: pharmaceuticals, Health and beauty goods, Nutraceutical preparations, nutritional products, dietetic food and substances, Dietetic foodstuffs and substances adapted for medical use, Dietetic food and substances for babies adapted for medical use, Functional foodstuffs and nutraceuticals for medical purposes, Nutritional additives for medical purposes, Dietary supplements for human beings, Medical preparations for food, nutritional, dietetic, vitamin, nutraceutical, probiotic, prebiotic and pharmaceutical use, pharmaceuticals and food supplements, Bacteriological preparations, other than for medical and veterinary use, Bacteriological cultures for adding to food, milk and dairy products, including fermented milk products, Not for medical or veterinary purposes, Cultures of microorganisms other than for medical use, cultures of microorganisms for use in making food and beverages, preparations based on microorganisms, Not for medical or veterinary purposes, bacterial substances for industrial use, Bacteria for use in food manufacture, Chemical preparations for use in cosmetic products, Bacterial preparations for the food industry, Bacterial cultures for addition to food products, Bacterial preparations and cultures not for medical use, Milk ferments and bacterial preparations for use in producing foodstuffs, Antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria for producing lactic acid and probiotic compositions, all for use in producing the following goods: pharmaceuticals, Dietetic compounds for humans, Baby food, Nutritional supplements, Nutritional supplements, dietary supplements, Dietary supplements for medical purposes and dietetic food, probiotic bacteria for the food industry, Probiotic bacterial preparations (not for medical use), fermentation extracts for industrial purposes, Probiotic bacterial preparations for medical purposes and for animals; Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: Cosmetics featuring live or dead microorganisms, cosmetics and cosmetic preparations based on microorganisms, lactic bacteria and/or bifidobacteria, functional cosmetics based on microorganisms, lactic bacteria and/or bifidobacteria, non-medicated cosmetics, Cosmetics featuring hyaluronic acid and microorganisms; Wholesaling and retailing for others including via mail order and via communications media including the internet, in relation the following goods: Preparations of microorganisms for medical and veterinary purposes, Bacteriological preparations for medical and veterinary use, Pharmaceutical products and preparations, namely pharmaceutical preparations, parapharmaceuticals, milk ferments, probiotic ferments, probiotics, nutraceuticals, nutritional products, pharmaceuticals and food supplements, Bacteriological cultures for adding to milk, dairy products and fermented milk products, for medical use, food additives based on milk and dairy products, including fermented milk products, for use as dietary supplement (not for medical use), vitamins, Dietary fiber to aid digestion, Dietary fibre for use as an ingredient in the production of dietary supplements, Vitamin-fortified beverages, Dietetic beverages adapted for medical, Dietetic food and substances adapted for medical use, dietetic food and substances for babies for medical use, functional and nutraceutical food, not for medical use, dietary supplements for medical use and dietary supplements for human beings featuring at least one of the following compounds: trace elements, mineral salts, Metal oxides, Metal hydroxides, Phosphoric acid salts, vitamins, Proteins, milk protein, Microelements, organic acids and salts thereof, inorganic acids and salts thereof, saturated or unsaturated fatty acids, oils, fats and lipids of plant and/or animal origin, amino acids, Glucose, Starch, rice starch, Carbohydrates, Saccharic esters in fatty acids, Lecithin and Sunflower lecithin, omega 3 and omega-6.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
Produits et services
Raw materials being chemical, chemicals, additives and chemical compounds intended for industry for use in the manufacture of pharmaceutical, parapharmaceutical, nutraceutical, nutritional, food and dietary substances, food and dietary substances for medical use, dietary food and substances for babies for medical use, functional and nutraceutical food for medical use, food supplements for medical use, food supplements for humans, pharmaceutical products and food supplements; bacteriological preparations other than those for medical and veterinary use; bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use; cultures of microorganisms not for medical or veterinary purposes; cultures of microorganisms for use in the manufacture of food and beverages, other than for medical or veterinary use; preparations being cultures of microorganisms, not for medical or veterinary use; bacterial preparation substances for industrial use, other than for medical or veterinary use; bacterial preparations used in food production, other than for medical or veterinary use; perfluorinated chemical compounds prepared synthetically for use in the manufacture of cosmetics; bacterial preparations for the food industry, other than for medical or veterinary use; additive bacterial cultures for food products, other than for medical or veterinary use; bacterial preparations and cultures not for medical use and addition to food products; lactic fermentation extracts and bacterial preparations used for production of foods, other than for medical or veterinary use; chemicals and chemical preparations, namely, antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds, all intended for the manufacture of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods; probiotic bacteria for use in the manufacture of food supplements; preparations of probiotic bacteria not for medical use, for use in the manufacture of food supplements; fermentation extracts for industrial use Preparations of microorganisms for medical or veterinary use; bacteriological preparations for medical and veterinary use; pharmaceutical products and preparations, namely, pharmaceutical products for the treatment of indigestion, parapharmaceutical for the treatment of indigestion, lactic ferments for pharmaceutical purposes, probiotic ferments for pharmaceutical purposes, probiotic supplements, nutraceuticals for use as a dietary supplement, nutritional supplements; pharmaceutical products for the treatment of infectious diseases; food supplements; bacteriological culture preparations to add to milk, dairy products and fermented milk for medical purposes; lactic bacterial preparations for medical purposes; dietary supplements being comprised of milk and dairy products, including fermented milk products; vitamins; dietary fibers to aid digestion; dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin supplement drinks, dietary supplement drinks for medical use; dietary and nutritional supplements, namely, food and dietetic substances for medical use, food and dietetic substances for infants for medical use, functional foods and nutraceuticals for medical use, food supplements for medical use and food supplements for humans comprising at least one selected compound trace elements, mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated or unsaturated fatty acids, oils, fats and lipids of vegetable origin and animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6; probiotic bacterial preparations for medical and veterinary use Wholesale and retail store services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to raw materials in the nature of chemical, chemicals, additives and chemical compounds intended for industry for formulation and preparation of pharmaceutical, parapharmaceutical, nutraceutical, nutritional, food and dietary substances, food and dietary substances for medical use, dietary food and substances for babies for medical use, functional and nutraceutical food for medical use, food supplements for medical use, food supplements for humans, medical preparations, namely, medical devices, pharmaceutical products and food supplements, bacteriological preparations other than those for medical and veterinary use, bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use, cultures of microorganisms not for medical purposes, cultures of microorganisms for use in the manufacture of food and beverages, preparations based on microorganisms, not for medical or veterinary use, bacterial substances for industrial use, bacteria used in food production, chemical preparations for cosmetics, bacterial preparations for the food industry, additive bacterial cultures for food products, bacterial preparations and cultures not for medical use, lactic ferments and bacterial preparations used for production of foods, antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds all intended for the production of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods, probiotic bacteria for the food industry, preparations of probiotic bacteria not for medical use, fermentation extracts for industrial use, probiotic bacterial preparations for medical and animal use; wholesale and retail store services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to preparations of microorganisms for medical or veterinary use, bacteriological preparations for medical and veterinary use, pharmaceutical products and preparations, including pharmaceutical products, parapharmaceuticals, lactic ferments, probiotic ferments, probiotics, nutraceuticals, nutritional, medical preparations, namely, medical devices, pharmaceutical products and food supplements, bacteriological cultures to add to milk, dairy products and fermented milk for medical purposes, lactic bacteria for medical purposes, food additives based on milk and dairy products, including fermented milk products, for use as a dietary supplement not for medical purposes, vitamins, dietary fibers to aid digestion, dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin drinks, dietary drinks for medical use, food and dietetic substances for medical use, food and dietetic substances for infants for medical use, functional foods and nutraceuticals for medical use, food supplements for medical use and food supplements for humans comprising at least one selected compound trace elements, mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated or unsaturated fatty acids, oils, fats and lipids of vegetable origin and animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
Produits et services
(1) Active chemical ingredients for use in the manufacture of food, of medicine, of pharmaceuticals, parapharmaceuticals, nutraceuticals; chemical additives for use in the manufacture of food, of medicine, of pharmaceuticals, parapharmaceuticals, nutraceuticals; chemical compositions for use in the manufacture of food, of medicine, of pharmaceuticals, parapharmaceuticals, nutraceuticals; chemical compounds for use in the manufacture of food, of medicine, of pharmaceuticals, parapharmaceuticals, nutraceuticals, in accordance with EU regulation 2017/745; bacteriological preparations for the food industry; bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use; cultures of bacterial microorganisms for laboratory and scientific research; cultures of microorganisms for use in the manufacture of food and beverages; bacteria used in food production; chemical preparations for use in the manufacture of cosmetics; bacterial preparations for the food industry; additive bacterial cultures for food products; bacterial preparations and cultures for the food industry; lactic ferments and bacterial preparations used for production of foods; antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds all intended for the production of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods; probiotic bacteria for the food industry; preparations of probiotic bacteria for the food industry; fermentation extracts for industrial use, namely biological microorganisms used in the manufacture of pharmaceuticals.
(2) Dietary supplements containing microorganisms for gastrointestinal health; probiotic bacterial formulations for medical and veterinary use; pharmaceutical products and preparations, namely pharmaceutical products, parapharmaceuticals, lactic ferments, probiotic ferments, probiotics, nutraceuticals, and nutritional supplements for gastrointestinal health; pharmaceutical products and food supplements for gastrointestinal health, in accordance with EU regulation 2017/745; bacteriological cultures to add to milk, dairy products and fermented milk for medical purposes; lactic bacteria for medical purposes; food additives based on milk and dairy products, including fermented milk products, for use as a dietary supplement (not for medical purposes); vitamins; dietary fibers to aid digestion; dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin drinks, dietary drinks for medical use; food preparations for babies and infants; mineral food supplements, namely food supplements containing at least one selected compound trace elements of mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated and unsaturated fatty acids, oils, fats and lipids of vegetable origin and animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6; probiotic bacterial preparations for medical and animal use. (1) Wholesale and retail services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to raw materials [chemical], chemicals, additives and chemical compounds intended for industry for formulation and preparation of pharmaceutical, parapharmaceutical, nutraceutical, nutritional, food and dietary substances, food and dietary substances for medical use, dietary food and substances for babies for medical use, functional and nutraceutical food for medical use, food supplements for medical use, food supplements for humans, medical preparations, namely medical devices pursuant to EU regulation 2017/745, pharmaceutical products and food supplements, in accordance with EU regulation 2017/745, bacteriological preparations other than those for medical and veterinary use, bacteriological cultures to be added to foods, milk and dairy products, including fermented milk products, other than for medical and veterinary use, cultures of microorganisms not for medical purposes, cultures of microorganisms for use in the manufacture of food and beverages, preparations based on microorganisms, not for medical or veterinary use, bacterial substances for industrial use, bacteria used in food production, chemical preparations for cosmetics, bacterial preparations for the food industry, additive bacterial cultures for food products, bacterial preparations and cultures not for medical use, lactic ferments and bacterial preparations used for production of foods, antioxidants, fatty acids, proteins, enzymes, liposomes, cultures of microorganisms, bacteria to produce lactic acid and probiotic compounds all intended for the production of pharmaceuticals, dietary compounds for human use, baby food, food supplements, nutritional supplements, dietary supplements, food supplements for medical use and dietary foods, probiotic bacteria for the food industry, preparations of probiotic bacteria [not for medical use], fermentation extracts for industrial use, probiotic bacterial preparations for medical and animal use; wholesale and retail services for the benefit of third parties including by mail order and through the means of communication including the internet, in relation to preparations of microorganisms for medical or veterinary use, bacteriological preparations for medical and veterinary use, pharmaceutical products and preparations, including pharmaceutical products, parapharmaceuticals, lactic ferments, probiotic ferments, probiotics, nutraceuticals, nutritional, medical preparations, namely medical devices pursuant to EU regulation 2017/745, pharmaceutical products and food supplements, in accordance with EU regulation 2017/745, bacteriological cultures to add to milk, dairy products and fermented milk for medical purposes, lactic bacteria for medical purposes, food additives based on milk and dairy products, including fermented milk products, for use as a dietary supplement (not for medical purposes), vitamins, dietary fibers to aid digestion, dietary fibers for use as an ingredient in the manufacture of dietary supplements, vitamin drinks, dietary drinks for medical use, food and dietetic substances for medical use, food and dietetic substances for infants for medical use, functional foods and nutraceuticals for medical use, food supplements for medical use and food supplements for humans comprising at least one selected compound trace elements, mineral salts, oxides of metals, metal hydroxides, phosphoric acid salts, vitamins, proteins, milk proteins, microelements, organic acids and their salts, inorganic acids and their salts, saturated or unsaturated fatty acids, oils, fats and lipids of vegetable origin and animal, amino acids, glucose, starch, rice starch, carbohydrates, saccharic esters of fatty acids, sunflower lecithin and lecithin, omega-3 and omega-6.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceuticals, medical and veterinary preparations, namely, pain relief medication and antibiotics; sanitary preparations for medical purposes; dietetic food and beverages adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; medical plasters, medical dressings; dietetic food and beverages for babies; dietetic food and beverages for babies adapted for medical use; food supplements; dietary supplements; nutraceuticals for use as dietary supplements; medicated supplements for foodstuffs for babies and animals; Nutraceuticals for use as a dietary supplement for medical purposes; nutritional food additives for medical use in the nature of natural food extracts derived from fish, meat, and vegetables; dietetic foods adapted for special medical use; medical preparations, namely, nutritional supplements; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; delivery agents in the form of tablets for the delivery of dietary supplements; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals and veterinary active substances; pharmaceutical preparations for inhalers for the treatment of respiratory diseases and disorders; medicinal preparations for the mouth and as sprays; inhalant anesthetics Surgical apparatus and instruments for medical, dental or veterinary use; therapeutic and assistive devices adapted for persons with disabilities, namely, medical and therapeutic device and apparatus, namely, a force and motion sensing apparatus and assisted exercise machine for the rehabilitation of hands and wrists, feet and ankles, knees affected by neuromuscular diseases, disorders, or injuries for home or clinical use; apparatus, devices and articles for nursing infants, namely, nursing bottles; inhalers for medical use; spray bottles being vaporizers for medical use; spray cans in the nature of aerosol dispenser for medical use; aerosol dispenser for medical purposes; dropping pipetting instruments for medical use; apparatus for administering drugs by inhalation, namely, inhalers for medical use
36 - Services financiers, assurances et affaires immobilières
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Promoting public awareness of treatment guidelines; promoting public awareness of inflammatory and autoimmune diseases; Administratively assisting patients in enrolling in pharmaceutical reimbursement and benefit programs. Financially assisting patients, pharmacists, and healthcare providers with respect to reimbursement of medicines. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; dietetic food
and substances adapted for medical or veterinary use, food
for babies; dietary supplements for human beings and
animals; plasters, materials for dressings, dietetic food
and substances for babies; dietetic food and substances for
babies adapted for medical use; food supplements; dietary
supplements; nutraceuticals for use as dietary supplements;
functional foodstuffs and nutraceuticals for medical
purposes; nutritional additives for medical use; foods for
special medical purposes; medical preparations, in
particular pharmaceuticals pursuant to regulation EU
2017/745; drug delivery agents; delivery agents for dietary
supplements; pharmaceutical and veterinary substances;
pharmaceutical preparations for inhalers; medicinal sprays;
inhalants. Surgical, medical, dental and veterinary apparatus and
instruments; therapeutic and assistive devices adapted for
persons with disabilities; apparatus, devices and articles
for nursing infants, inhalers for medical use; spray bottles
[vaporizers] for medical use; cans [spray] for medical use;
aerosol dispenser for medical purposes; pipetting
instruments for medical use; apparatus for administering
drugs by inhalation.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; dietetic food
and substances adapted for medical or veterinary use, food
for babies; dietary supplements for human beings and
animals; plasters, materials for dressings; dietetic food
and substances for babies; dietetic food and substances for
babies adapted for medical use; food supplements; dietary
supplements; nutraceuticals for use as dietary supplements;
functional foodstuffs and nutraceuticals for medical
purposes; nutritional additives for medical use; foods for
special medical purposes; medical preparations, in
particular medical devices pursuant to regulation EU
2017/745; drug delivery agents; delivery agents for dietary
supplements; active ingredients and pharmaceutical and
veterinary active substances; pharmaceutical preparations
for inhalers; medicinal sprays; inhalants. Surgical, medical, dental and veterinary apparatus and
instruments; therapeutic and assistive devices adapted for
persons with disabilities; apparatus, devices and articles
for nursing infants; inhalers for medical use; spray bottles
[vaporizers] for medical use; cans [spray] for medical use;
aerosol dispenser for medical purposes; pipetting
instruments for medical use; apparatus for administering
drugs by inhalation.
96.
PHARMACEUTICAL COMPOSITIONS IN THE FORM OF GEL CONTAINING XYLOGLUCAN AND ALCOHOLS FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS
The invention relates to gel compositions comprising pharmaceutical active ingredients. The composition comprises xyloglucan at a concentration between 0.1% and 10.0% by total weight of the composition, together with a primary alcohol at a concentration between 20.0 and 50.0% by total weight of the composition. The invention also describes a process for the preparation of the composition and its use in the treatment of pathologies wherein a controlled release of the active principle is useful.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceutical preparations for treating digestive system
disorders; pharmaceutical preparations and substances for
the treatment of gastrointestinal diseases; medicines for
the treatment of gastrointestinal diseases; pharmaceutical
preparations and substances for the treatment of
gastroesophageal reflux; pharmaceutical preparations and
substances for the protection of the esophagus in case of
gastroesophageal reflux; pharmaceutical preparations for the
treatment of digestive diseases. Medical devices for the treatment of gastrointestinal
diseases; medical devices for treating gastroesophageal
reflux; medical devices for the protection of the esophagus
in case of gastroesophageal reflux.
36 - Services financiers, assurances et affaires immobilières
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Promoting public awareness of treatment guidelines; promoting public awareness of inflammatory and autoimmune diseases; assisting patients in enrolling in pharmaceutical reimbursement and benefit programs. Assisting patients, pharmacists, and healthcare providers with respect to reimbursement of medicines. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
Produits et services
Active chemical ingredients, Raw materials [chemicals], Semi-processed chemicals, Active ingredients and pharmaceutical active substances, all the aforesaid goods being used individually or in combination for the manufacture of the following goods: pharmaceuticals intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, for the manufacture of medical preparations intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, for the manufacture of food supplements intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, for the manufacture of nutraceuticals for use as dietary supplements intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, for the manufacture of medical preparations, in particular medical devices in accordance with regulation (EU) 2017/745 intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, and for the manufacture of pharmaceutical preparations for inhalers, medicinal sprays, inhalants. Pharmaceuticals, medical preparations; Dietetic substances adapted for medical use; Food supplements; Nutraceuticals for use as dietary supplements; Medical preparations, in particular medical devices in accordance with Regulation (EU) 2017/745; Pharmaceutical preparations for inhalers; Medicinal sprays; Inhalants; all the aforesaid goods are intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts, and for the treatment of diseases or disorders of the respiratory system. Inhalers for medical use; Vaporizers for medical purposes; Aerosol dispensers for medical purposes; Apparatus for administering drugs by inhalation. Online retailing, Retailing and wholesaling, Marketing, Advertisement services, Presentation of goods on communication media, for retail purposes, Arranging and conducting of promotional events, All the aforesaid relating to the following goods: Active chemical ingredients, Raw materials [chemicals], Semi-processed chemicals, Active ingredients and pharmaceutical active substances, all the aforesaid goods being used individually or in combination for the production of the following goods: pharmaceuticals intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, for the manufacture of medical preparations intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, for the manufacture of dietary supplements intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, for the manufacture of functional foodstuffs and nutraceuticals for medical purposes intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, for the manufacture of medical preparations, in particular medical devices in accordance with regulation (EU) 2017/745 intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts and for the treatment of diseases or disorders of the respiratory system, and for the manufacture of pharmaceutical preparations for inhalers, medicinal sprays, inhalants; Online retailing, Retailing and wholesaling, Marketing, Advertisement services, Presentation of goods on communication media, for retail purposes, Arranging and conducting of promotional events, All the aforesaid relating to the following goods: pharmaceuticals, Medical preparations, Dietetic substances adapted for medical or veterinary use, dietary supplements, Functional foodstuffs and nutraceuticals for medical purposes, Pharmaceutical preparations for inhalers, Medicinal sprays, Inhalants, Medical preparations in particular medical devices in accordance with Regulation (EU) 2017/745, all the aforesaid goods are intended for the maintenance of the physiological conditions of the upper and lower respiratory tracts, and for the treatment of diseases or disorders of the respiratory system; Online retailing, Retailing and wholesaling, Marketing, Advertisement services, Presentation of goods on communication media, for retail purposes, Arranging and conducting of promotional events, All the aforesaid relating to the following goods: inhalers for medical use, Vaporisers for medical purposes, Aerosol dispensers for medical purposes, Aerosol dispensers for medical purposes, Apparatus for administering drugs by inhalation.
100.
Compounds useful for increasing neurogenesis in neural tissue
The invention described herein is directed to the use of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in which said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.
A61K 31/21 - Esters, p. ex. nitroglycérine, sélénocyanates
A61K 31/205 - Sels d'addition d'acides organiques avec des aminesSels d'ammonium quaternaire internes, p. ex. bétaïne, carnitine
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
